Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: physical function

How Do Reduced-Dose Glucocorticoids Plus Rituximab Affect ANCA-Associated Vasculitis?

Lara C. Pullen, PhD  |  October 13, 2021

Furuta et al. evaluated the benefits of reducing glucocorticoid doses during remission induction for patients with ANCA-associated vasculitis. The researchers found a reduced-dose-glucocorticoid-plus-rituximab regimen was noninferior to a regimen of high-dose glucocorticoids plus rituximab in these patients.

Filed under:ConditionsVasculitis Tagged with:ANCA-Associated VasculitisGlucocorticoidsRemissionrituximab

HIPAA and PHI Cybersecurity Best Practices in the COVID-19 Era

Steven M. Harris, Esq.  |  September 14, 2021

When the first SARS-CoV-2 case was recorded, it was difficult to appreciate the extent to which cybersecurity concerns, particularly in connection to the protection of patient healthcare data, would enter into main­stream consciousness. Although many practices and healthcare organizations have recently adopted additional measures to safeguard patients’ protected health information (PHI) through expanded cybersecurity monitoring,…

Filed under:Legal Updates Tagged with:HIPAAprotected health information

Using Different Fibromyalgia Criteria Affects Prevalence Estimates

Deborah Levenson  |  September 14, 2021

A recent paper illustrates how using different fibromyalgia criteria affects reports of its prevalence.1 Writing in Arthritis Care & Research, researchers found the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks–American Pain Society Pain Taxonomy (AAPT) criteria caused far more people to be categorized as having fibromyalgia than criteria put forth by…

Filed under:ConditionsPain SyndromesSoft Tissue Pain Tagged with:Classification CriteriaFibromyalgia

Case Report: Sarcoidosis in Patient with History of IgG4-Related Disease

Veronica Matto, DO, Rajshri Shah, MD, Jie Ouyang, MD, PhD, Cory Perugino, DO, & Joseph J. LaConti, MD, PhD  |  September 14, 2021

Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:IgG4 related diseaseSarcoidosis

Case Report: A 5-Year-Old with an Ischemic Digit

Marta Michalska-Smith, MD, & Colleen K. Correll, MD, MPH  |  September 14, 2021

Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…

Filed under:Conditions Tagged with:Aicardi-Goutières SyndromeJanus Kinase Inhibitors

Healthcare Extenders Can Reduce Physician Burden & Improve Patient Access & Care

Kimberly Steinbarger, PT, MHS, DHSc, & Saba Mohiuddin, PharmD, BCACP  |  August 11, 2021

In the early 1900s, the treatment for rheumatic and musculoskeletal disease (RMD) was primarily targeted at symptomatic relief and included analgesics, physical therapy, splinting and bed rest. With the discovery of methotrexate and its impact on rheumatoid arthritis (RA) management, a much-needed evolution of medications targeting disease activity began. Over the past 30 years, several…

Filed under:Interprofessional PerspectiveWorkforce Tagged with:Advanced Practice CliniciansAssociation of Rheumatology Professionals (ARP)dietitiannurse practitioneroccupational therapistspharmacistphysical therapistphysician assistantssocial worker

Achieving Excellence in Pediatric Rheumatology Clinical Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

PRSYM—At its heart, the practice of medicine in all forms is specifically centered on delivering compassionate, thoughtful and evidence-based clinical care. In the world of pediatric rheumatology, a range of issues, such as chronic pain, reproductive health and transitioning to adult providers, are of utmost importance to patients and physicians alike. These topics were addressed…

Filed under:ConditionsMeeting ReportsPain SyndromesPediatric Conditions Tagged with:Chronic painpatient carePediatricPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMreproductive healthtransition

Generally Favorable Outcomes 6 Months After COVID-Linked Inflammatory Syndrome in Kids

Reuters Staff  |  July 15, 2021

NEW YORK (Reuters Health)—A six-month assessment of children with pediatric inflammatory multisystem syndrome temporally associated with COVID-19 disease (PIMS-TS) show generally favorable outcomes, but also a range of lingering issues. Cardiac, gastrointestinal, renal, hematology and otolaryngology problems largely resolved at six months, but muscular fatigue and emotional lability were common. Long-term, serious end-organ damage occurred…

Filed under:ConditionsPediatric Conditions Tagged with:ChildrenCOVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)Pediatricpediatric inflammatory multisystem syndrome temporally associated with COVID-19 disease (PIMS-TS)

Webside Care Can Enhance Rheumatology Training & Patient Satisfaction

Lisa Zickuhr, MD, Jason Kolfenbach, MD, & Marcy B. Bolster, MD  |  July 15, 2021

Many practitioners can relate to the epiphany of Roy Basch, MD, the lead character in Samuel Shem’s satirical novel The House of God.1 During his first on-call shift as a medicine intern, long work hours combined with jaded advice from his senior resident leave Dr. Basch feeling disenchanted with the medical profession until he cares…

Filed under:Education & TrainingPatient Perspective Tagged with:telemedicinewebside care

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARoutcomeOutcome measuresPsoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 81
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences